<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976258</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-00336 and IRB17-00429</org_study_id>
    <secondary_id>1R01DA044576-01</secondary_id>
    <nct_id>NCT03976258</nct_id>
  </id_info>
  <brief_title>Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV</brief_title>
  <official_title>The Impact of Intravenous Heroin Use on Immune Activation in Treated HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the advent of safer HIV therapies, high levels of markers of systemic inflammation&#xD;
      and increased cardiovascular risk threaten the well-being of individuals living with HIV and&#xD;
      present a significant challenge for HIV providers. These risks may be accentuated in&#xD;
      HIV-infected individuals who are active intravenous drug users (IVDU); however, this&#xD;
      population has been specifically excluded from prior studies assessing immune activation and&#xD;
      cardiovascular risk in people living with HIV. In this study, the investigators will&#xD;
      specifically target HIV-infected participants who are active IVDU, and co-enroll a control&#xD;
      group of HIV-infected participants who never used IV drugs. The investigators will study the&#xD;
      specific alterations in immune activation and several mechanisms felt to be potential drivers&#xD;
      of immune activation outside of the IVDU population, namely gut integrity alteration,&#xD;
      microbial translocation, and oxidized lipids. The investigators will also study the effect of&#xD;
      IVDU on markers of arterial inflammation and vascular function. Importantly, the&#xD;
      investigators will study the reversibility of immune activation, gut dysfunction, and&#xD;
      cardiovascular markers after cessation of IVDU, and to that effect, compare strategies for&#xD;
      IVDU cessation-buprenorphine/naloxone versus methadone or vivitrol maintenance treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 48-week matched, prospective, observational, cohort study of HIV-infected adults on&#xD;
      antiretroviral therapy who actively use heroin or who have never used heroin. The overarching&#xD;
      goals are 1) to define the extent and specifics of immune activation in HIV-infected IV&#xD;
      heroin users; 2) to define the effect of IV heroin on gut integrity and permeability, and the&#xD;
      relationship of gut integrity alteration and immune activation; 3) importantly, to study the&#xD;
      reversibility of immune activation, inflammation, and gut dysfunction after cessation of IV&#xD;
      heroin, and to that effect, compare strategies for medication assisted&#xD;
      treatment-buprenorphine/naloxone versus methadone or vivitrol maintenance; 4) to study if&#xD;
      heightened immune activation associated with active intravenous drug use (IVDU) is associated&#xD;
      with higher cardiovascular disease risk, including endothelial dysfunction and arterial&#xD;
      inflammation, and if these effects are reversible with buprenorphine/naloxone or methadone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma soluble CD14 concentration</measure>
    <time_frame>48 weeks</time_frame>
    <description>soluble marker of monocyte activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Endopat measure of microvascular function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measure of endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in target to background ratio measured by fluorodeoxyglucose (FDG)-positron emission tomography (PET)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measure of vascular inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma Interferon Gamma-Induced Protein 10 concentration</measure>
    <time_frame>48 weeks</time_frame>
    <description>soluble marker of inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma intestinal fatty acid binding protein concentration</measure>
    <time_frame>48 weeks</time_frame>
    <description>soluble marker of gut integrity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in total fat stores measured by Whole body Dual-energy X-ray absorptiometry</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measurement of fat stores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aortofemoral pulse wave velocity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measure of arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change is waist to hip ratio</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measurement of central obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index</measure>
    <time_frame>48 weeks</time_frame>
    <description>Body measurement</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>HIV Infection</condition>
  <condition>Opioid-use Disorder</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>HIV-infected adults actively using heroin</arm_group_label>
    <description>HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected adults never having used heroin</arm_group_label>
    <description>HIV-infected adults on antiretroviral therapy matched to HIV-infected adults actively using heroin by age, sex and CD4+ count.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected adults initiating buprenorphine/naloxone</arm_group_label>
    <description>HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-uninfected adults initiating buprenorphine/naloxone</arm_group_label>
    <description>HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with buprenorphine/naloxone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected adults initiating methadone</arm_group_label>
    <description>HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected adults initiating Vivitrol</arm_group_label>
    <description>HIV-infected adults on antiretroviral therapy who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-uninfected adults initiating methadone</arm_group_label>
    <description>HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with methadone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-uninfected adults initiating Vivitrol</arm_group_label>
    <description>HIV-uninfected adults who are currently using heroin at least 1 month with a cumulative duration of at least 12 months in the past initiating medication assisted treatment (MAT) for opioid use disorder with Vivitrol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine/naloxone</intervention_name>
    <description>This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.</description>
    <arm_group_label>HIV-infected adults initiating buprenorphine/naloxone</arm_group_label>
    <arm_group_label>HIV-uninfected adults initiating buprenorphine/naloxone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.</description>
    <arm_group_label>HIV-infected adults initiating methadone</arm_group_label>
    <arm_group_label>HIV-uninfected adults initiating methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone Injection</intervention_name>
    <description>This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.</description>
    <arm_group_label>HIV-infected adults initiating Vivitrol</arm_group_label>
    <arm_group_label>HIV-uninfected adults initiating Vivitrol</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heroin</intervention_name>
    <description>This is an observational study. Participants using heroin will be enrolled into this group.</description>
    <arm_group_label>HIV-infected adults actively using heroin</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, urine, stool, peripheral blood mononuclear cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults ages 18 to 80 years with and without HIV infection using heroin or initiating&#xD;
        treatment for heroin use or not using heroin.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infection or no HIV infection&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  HIV-1 RNA &lt; 400 if HIV-infected and on antiretroviral therapy&#xD;
&#xD;
          -  On stable antiretroviral therapy at least 12 weeks with cumulative duration of at&#xD;
             least a year for HIV-infected if on antiretroviral therapy&#xD;
&#xD;
          -  Currently using heroin at least 1 month with a cumulative duration of at least 12&#xD;
             months in the past for active heroin group&#xD;
&#xD;
          -  Initiating medication assisted treatment for active heroin use initiating medication&#xD;
             assisted treatment groups&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection, malignancy or other inflammatory condition&#xD;
&#xD;
          -  Uncontrolled diabetes or hypothyroidism&#xD;
&#xD;
          -  Known cardiovascular disease&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrilynn O Hileman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grace A McComsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl A Smith, BA</last_name>
    <phone>216-778-7141</phone>
    <email>csmith@metrohealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danielle Labbato, RN</last_name>
    <phone>216-844-2739</phone>
    <email>Danielle.Labbato@UHhospitals.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Labbato, RN</last_name>
      <phone>216-844-2739</phone>
      <email>danielle.labbato@UHhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metrohealth Medical center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Smith, BA</last_name>
      <phone>216-778-7141</phone>
      <email>csmith15@metrohealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>Corrilynn Hileman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>heroin</keyword>
  <keyword>HIV</keyword>
  <keyword>inflammation</keyword>
  <keyword>cardiovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Heroin</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

